Co-promoting retinal health and meibomitis therapies

Article

Sirion Therapeutics Inc and Advanced Vision Research Inc (AVR) have agreed to co-promote AVR's MacuTrition (a nutritional supplement promoting retinal health) and NutiDox Convenience Kit (a meibomian gland therapy) in the US.

Sirion Therapeutics Inc and Advanced Vision Research Inc (AVR) have agreed to co-promote AVR's MacuTrition (a nutritional supplement promoting retinal health) and NutiDox Convenience Kit (a meibomian gland therapy) in the US.

The MacuTrition nutritional supplement combines antioxidants, anti-inflammatories and anti-angiogenics (including vitamins D and E, omega 3 and green tea extract) and aims to promote long-term eye health.

The NutriDox Convenience Kit, a treatment for meibomitis and meibomian gland dysfunction (MGD), comprises doxycycline 75 mg, a nutritional supplement addressing dry eye symptoms and a topical heat compress.

MacuTrition is available over-the-counter, and NutriDox is a prescription-only product. In addition to these AVR products, Sirion sales reps will also provide samples of TheraTears, AVR's range of products for the treatment of dry eye.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.